Research Studies

We are currently conducting several research studies that may help to improve understanding of the causes of mood and anxiety disorders and develop novel treatments to manage these illnesses. Some of these studies provide assessment and treatment at no charge and some studies provide reimbursement for your participation. If interested, please follow the study link to find out more about the specific study.

Studies Currently Open

Planned Future Studies

RGH-MD-24 (Allergan Inc.)

  • A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients with Schizophrenia
  • PI: Jayesh Kamath, M.D., Ph.D.

Depression & mHealth Study (National Institutes of Health)

  • Personalized Depression Treatment Supported by Mobile Sensor Analytics
  • PI: Bing Wang, PhD; Co-PI: Jayesh Kamath, M.D., Ph.D.

Suvorexant & mHealth Sleep Study (Merck Inc.)

  • Investigation of a Novel Mobile Health (mHealth) Technology Approach to Investigate Sleep Effects and Daytime Functioning in Depressed Patients with Comorbid Insomnia Receiving Co-administration of Suvorexant and an Antidepressant
  • PI: Jayesh Kamath, M.D., Ph.D.

Completed Studies

STAIR PTSD Study (National Institute of Mental Health)

  • Implementation of an Evidence Based PTSD Treatment in Public Sector Settings
  • PI: Jayesh Kamath, M.D., Ph.D.

Texting CIG (CICATS)

  • A Text Messaging Intervention to Improve Psychiatric Treatment Adherence: A Proof-of-Principle Study
  • PI: Jayesh Kamath, M.D., Ph.D.

FIRST Study (Janssen Inc.)

  • Family Intervention in Recent onset Schizophrenia Treatment (FIRST)
  • A 12-Month Randomized, Open-Label Study of Caregiver Psychoeducation and Skills Training in Patients Recently Diagnosed with Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder and Receiving Paliperidone Palmitate or Oral Antipsychotic Treatment
  • PI: Jayesh Kamath, M.D., Ph.D.

ASPIRE-2 (Janssen Inc.)

  • A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to Be at Imminent Risk for Suicide
  • PI: Jayesh Kamath, M.D., Ph.D.

LifeRhythm Study (National Science Foundation)

  • LifeRhythm: A Framework for Automatic and Pervasive Depression Screening Using Smartphones
  • PI: Bing Wang, Ph.D.; Co-PI: Jayesh Kamath, M.D., Ph.D.